Jaume Alijotas Reig Institutions of which they are part Head of group Systemic Diseases Vall Hebron Institut de Recerca Email Jaume Alijotas Reig Email Institutions of which they are part Head of group Systemic Diseases Vall Hebron Institut de Recerca
Research lines Predictive kit to detect the possible establishment of late adverse effects related to bioimplants used in clinical practice. A high variability in the prevalence of adverse effects with an immunologic basis seems to be related with any implant used in clinical practice. We have managed to find a particular association of HLA haplotypes that increase the risk for developing these effects up to 600 times. We are nowadays working on setting up a safe and reliable biochip or kit which predicts this risk easily in a routine test. IP: Jaume Alijotas Reig Immunobiology and immunopathology of recurrent pregnancy loses and spontaneous loses. Around 2-3% of reproductive-age couples suffer recurrent pregnancy loses. Almost 18% of couples that wish to have children suffer infertility problems. Simultaneously, 2-3% of all pregnant women are diagnosed with spontaneous loses. The expression of HLA molecules, specially type G, the degree of trophoblastic apoptosis, the outsourcing of new neoantigens such as phospholipids, the balance between Th1/Th2/Th3 cytokines, the type and quantity of CD4+CD25+Foxp3+ lymphocytes, the kind and the activity of uterine NK cells (uNK) cells, the presence or absence of blocking antibodies, and other mechanisms play different roles in the achievement of the so-called "tolerant microenvironment" needed to develop a normal pregnancy. Therefore, both autoimmune and alloimmune mechanisms are important. We aim at studying which isolated, and specially associated, anomalies can be identified as risk markers to be able to evaluate possible treatments. IP: Jaume Alijotas Reig Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3 Projects GLOBE: Gestación Ligada a Obesidad y al Entorno. Estudio longitudinal multicéntrico de factores de riesgo asociados a la obesidad en el embarazo IP: - Collaborators: Jaume Alijotas Reig, Inés Zulema Calero Fernández, Maite Avilés García Funding agency: Instituto de Salud Carlos III Funding: 135883 Reference: PI10/01367 Duration: 01/01/2011 - 31/12/2014 Heparina de Bajo Peso Molecular (HBPM) para la prevención de complicaciones derivadas de la insuficiencia placentaria en las pacientes de riesgo sin trombofilia: estudio multicéntrico randomizado IP: - Collaborators: Jaume Alijotas Reig, Inés Zulema Calero Fernández, Elisa Llurba Olivé, Josep Perapoch López Funding agency: Ministerio Sanidad Funding: 80000 Reference: EC10-205 Duration: 01/01/2011 - 31/12/2016 Envejecimiento endotelial y sus efectos pleiotrópicos sobre procesos inflamatorios, de la respuesta inmune y angiogénesis IP: Francesc Miro Mur Collaborators: Jaume Alijotas Reig, Simon Schwartz Navarro Funding agency: Fundación Invest. Médica Mutua Madrileña Funding: 36000 Reference: FMMA/05/2008 Duration: 24/09/2008 - 23/09/2011 CIBER: Bioingenieria, biomateriales y nanomedicina IP: - Collaborators: Manuel López Cano, Jaume Alijotas Reig, Francesc Miro Mur, Eloy Espín Basany Funding agency: CIBER Bioing., Biomateriales y Nanomedicina , BBN Funding: 480000 Reference: CB06/01/0012 Duration: 01/01/2007 - 31/12/2010 Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3
